World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.

Gotlib, Jason

Gotlib, Jason.

Affiliation

Gotlib J; Stanford Cancer Center, Stanford, California.

Am J Hematol ; 90(11): 1077-89, 2015 Nov.

Article in En | MEDLINE | ID: mdl-26486351

Subject(s)

Antineoplastic Agents/therapeutic use; Eosinophilia/diagnosis; Eosinophilia/therapy; Hematopoietic Stem Cell Transplantation; Adrenal Cortex Hormones/therapeutic use; Antibodies, Monoclonal/therapeutic use; Disease Management; Eosinophilia/classification; Eosinophilia/pathology; Eosinophils/drug effects; Eosinophils/metabolism; Eosinophils/pathology; Humans; Hydroxyurea/therapeutic use; Interferon-alpha/therapeutic use; Mutation; Receptor, Fibroblast Growth Factor, Type 1/genetics; Receptor, Platelet-Derived Growth Factor alpha/genetics; Receptor, Platelet-Derived Growth Factor beta/genetics; Risk Assessment

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hematopoietic Stem Cell Transplantation / Eosinophilia / Antineoplastic Agents Type of study: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Am J Hematol Year: 2015 Document type: Article Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google